Source: NewsOk

Myovant Sciences: Myovant Sciences: Fiscal 1Q Earnings Snapshot

LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $32.9 million in its fiscal first quarter.On a per-share basis, the London-based company said it had a loss of 37 cents.The results beat Wall Street expectations.Read more on

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating


Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more